BFNH on OTC
BIOFORCE NANOSCIENCES HOLDINGS, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Astrotech Corporation, SCIENTIFIC INDUSTRIES INC or Lifeloc Technologies, Inc, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2019
Where the money goes
Where each dollar of revenue went, fiscal 2019
- Cost of revenue75¢$13.4K
- Other costs25¢$4.4K
Out of $17.8K in revenue.34 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Board of Directors Compensation | $423.0K | $423.0K |
| General and Administrative | $67.0K | $67.4K |
| Total Expenses | $490.0K | $490.4K |
| Loss from Operations Before Loss on Liability Settlement | -$490.0K | -$490.4K |
| Loss on Liability Settlement | -$802.0K | |
| Net Loss | -$1.3M | -$490.4K |
| Weighted Average Number of Common Shares - Basic | 33.2M shares | 29.3M shares |
| Weighted Average Number of Common Shares - Diluted | 33.2M shares | 29.3M shares |
| Net Loss for the Period Per Common Shares - Basic | -$0.04 | -$0.02 |
| Net Loss for the Period Per Common Shares - Diluted | -$0.04 | -$0.02 |
Every line of the balance sheet in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $786 | $862 | |
| Total Current Assets | $786 | $862 | |
| Total Assets | $786 | $862 | |
| Accounts Payable and Accrued Expenses | $11.8K | $8.8K | |
| Accrued Board of Directors Compensation | $506.2K | $2.0M | |
| Due to Related Parties | $101.3K | $274.1K | |
| Total Current Liabilities | $619.3K | $2.3M | |
| Total Liabilities | $619.3K | $2.3M | |
| Common Stock - $0.001 Par; 900,000,000 Shares Authorized, 33,521,755 and 29,271,755 Issued and Outstanding, Respectively | $33.5K | $29.3K | |
| Additional Paid-In-Capital | $161.8M | $158.8M | |
| Accumulated Deficit | -$162.4M | -$161.1M | |
| Total Stockholders' Deficit | -$618.5K | -$2.3M | -$1.8M |
| Total Liabilities and Stockholders' Deficit | $786 | $862 | |
| Preferred stock, par value per share | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 100.0M shares | 100.0M shares | |
| Common stock, par value per share | $0.00 | $0.00 | |
| Common stock, shares authorized | 900.0M shares | 900.0M shares | |
| Common stock, shares issued | 33.5M shares | 29.3M shares | |
| Common stock, shares outstanding | 33.5M shares | 29.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Loss | -$1.3M | -$490.4K |
| Loss on Liability Settlement | $802.0K | |
| Accounts Payable and Accrued Expenses | $3.0K | $6.2K |
| Accrued Board of Directors Compensation | $421.8K | $423.0K |
| Net Cash Flows Used In Operating Activities | -$65.2K | -$61.2K |
| Capital Contributions | $8.1K | |
| Proceeds from Related Parties | $65.1K | $53.4K |
| Net Cash Flows Provided by Financing Activities | $65.1K | $61.5K |
| Net Change in Cash | -$76 | $224 |
Compare BIOFORCE NANOSCIENCES HOLDINGS, INC. with another company
Former names
- SILVER RIVER VENTURES, INC.Dec 14, 2004 to Feb 24, 20062
Recent filings
- Oct 7, 20268-K CURRENT REPORT
- Sep 4, 20263 PRIMARY DOCUMENT
- Sep 4, 20268-K CURRENT REPORT
- Sep 4, 2026SCHEDULE 13D
- Sep 3, 20263 PRIMARY DOCUMENT
- Sep 2, 20264 PRIMARY DOCUMENT
- Sep 2, 20264 PRIMARY DOCUMENT
- Aug 18, 20268-K CURRENT REPORT
- Aug 14, 20268-K CURRENT REPORT
- Aug 10, 202610-Q QTR. REPORT - JUNE 30, 2026
- Jul 7, 20268-K CURRENT REPORT
- Jul 1, 20268-K CURRENT REPOT
- Jun 18, 20268-K CURRENT REPORT
- May 19, 202610-Q QTR. REPORT - MARCH 31, 2026
- May 13, 2026NT 10-Q NOTIFICATION OF LATE FILING
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8